A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Neoplasms Clinical Trial

Official title:

A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04349280
• Other study ID #: 213152
• Status: Terminated
• Phase: Phase 1
• Start date: October 15, 2020
• Est. completion date: August 15, 2022

Study information

• Verified date: April 2024
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: August 15, 2022
• Est. primary completion date: August 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants can give signed informed consent/assent.

• Participants with histologically confirmed locally advanced or metastatic or locally advanced/unresectable urothelial carcinoma (including renal, pelvis, ureter, urinary bladder, urethra).

• Able to provide, a tumor tissue sample collected during screening and prior to administration of bintrafusp alfa.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

• Participants with adequate organ system functions.

• Life expectancy of at least 12 weeks.

• A female is eligible if she is not pregnant or breastfeeding.

Exclusion Criteria:

• Active brain and/or leptomeningeal disease that is symptomatic or requires therapeutic intervention. Participants with asymptomatic central nervous system (CNS) metastases who are clinically stable as demonstrated by serial brain images and have no requirement for corticosteroids for at least 14 days prior to enrollment are eligible.

• History of malignancy other than urothelial cancer within the last 3 years except for localized tumors that have been treated with curative intent or have not required therapy in the past 2 years. (e.g., resected non-melanoma skin cancer).

• No more than 2 lines of systemic therapy for the treatment of metastastic disease. If the most recent therapy was not a platinum-based regimen, the participant must have progressed on or after that therapy.

• Cirrhosis or current unstable liver or biliary disease per investigator assessment.

• Current pneumonitis or history of non-infectious pneumonitis that required systemic immunosuppressive treatment.

• Active autoimmune disease that required systemic immunosuppressive treatment within the past 2 years.

• Received prior allogeneic/autologous bone marrow or solid organ transplant.

• Receiving systemic corticosteroids (>10 milligrams [mg] daily oral prednisone or equivalent) or other immunosuppressive agent within 7 days prior to study treatment. Inhaled or topical steroids are permitted.

• Known severe hypersensitivity reactions to monoclonal antibodies or any ingredient used in the study treatment formulation (Grade >=3 National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0).

• Active infection requiring systemic therapy.

• Received any live vaccine within 30 days prior first dose of intervention.

• Known history of positive test for human immunodeficiency virus (HIV) with the exception of participants with cluster of differentiation 4 (CD4) + T-cell (CD4+) counts >=350 cells per microliter (cells /uL) and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.

• Active hepatitis B virus (HBV) (HBV surface antigen-positive).

• Active hepatitis C virus (HCV) infection, or positive HCV antibody, with the exception of participants that 1. Have HCV viral load below the limits of quantitation and 2. Completed curative antiviral therapy or are receiving and compliant with antiviral therapy.

• History or evidence of cardiac abnormalities within the 6 months prior to first dose of intervention.

• Participants with history of bleeding diathesis or recent major bleeding events considered by the Investigator as high risk for investigational drug treatment are also excluded.

• Any other serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results.

• Received prior systemic anti-cancer therapy within 2 weeks prior to study treatment.

• Received prior therapy with an anti-programmed death 1 (PD-1), anti-programmed death Ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

• Received prior therapy targeting transforming growth factor (TGF) beta - (e.g., Galunistertib).

• Received radiation therapy (or other non-systemic disease therapy) within 2 weeks prior to study treatment.

• Undergone major surgery within 4 weeks prior to administration of study treatment.

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• Bintrafusp alfa
Participants will receive bintrafusp alfa.

Locations

Country	Name	City	State
Canada	GSK Investigational Site	Toronto	Ontario
France	GSK Investigational Site	Bordeaux
France	GSK Investigational Site	Poitiers Cedex
France	GSK Investigational Site	Toulouse Cedex 9
France	GSK Investigational Site	Villejuif Cedex
Netherlands	GSK Investigational Site	Amsterdam
Spain	GSK Investigational Site	Barcelona
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Sevilla
United States	GSK Investigational Site	Cincinnati	Ohio
United States	GSK Investigational Site	Lake Success	New York

Sponsors (2)

Lead Sponsor	Collaborator
GlaxoSmithKline	Merck KGaA, Darmstadt, Germany

Countries where clinical trial is conducted

United States,  Canada,  France,  Netherlands,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Confirmed Overall Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1	Confirmed overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<)10 millimeters (mm).	Up to approximately 22 months
Secondary	Number of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs)	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity and is a congenital anomaly/birth defect. AEs which start or worsen on or after Bintrafusp alfa infusion are defined as treatment-emergent.	Up to approximately 22 months
Secondary	Number of Participants With Worst Grade Treatment Emergent AEs	Treatment emergent adverse events were analyzed using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Graded from Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL), Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE. Higher grade indicates more severe condition. AEs which start or worsen on or after Bintrafusp alfa infusion are defined as treatment-emergent.	Up to approximately 22 months